# Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis

> **NCT02344511** · PHASE3 · WITHDRAWN · sponsor: **Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)**

## Conditions studied

- Osteomyelitis

## Interventions

- **DRUG:** Dalbavancin
- **DRUG:** cefazolin, nafcillin, oxacillin or vancomycin

## Key facts

- **NCT ID:** NCT02344511
- **Lead sponsor:** Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-03
- **Primary completion:** 2018-10
- **Final completion:** 2019-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02344511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02344511, "Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02344511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*